In medulloblastoma, ErbB2 overexpression upregulates prometastatic genes, increases the migration of medulloblastoma cells, and has been associated with advanced metastatic disease and poor clinical outcome 2,9,10. Here, ERBB2 is linked to medulloblastoma.